NCT02688608View on ClinicalTrials.gov

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2021

Conditions
Anaplastic Thyroid Cancer
Interventions
DRUG

Pembrolizumab

200 mg IV once every 3 weeks

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Saad A Khan

OTHER

NCT02688608 - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter